Literature DB >> 26828753

Facilitatory effects of fetuin-A on atherosclerosis.

Chisato Naito1, Mio Hashimoto1, Kaho Watanabe1, Remina Shirai1, Yui Takahashi1, Miho Kojima1, Rena Watanabe1, Kengo Sato1, Yoshitaka Iso2, Taka-Aki Matsuyama3, Hiroshi Suzuki2, Hatsue Ishibashi-Ueda3, Takuya Watanabe4.   

Abstract

OBJECTIVE: Fetuin-A is a circulating glycoprotein that is produced by liver and adipose tissue. Fetuin-A is known to induce insulin resistance and suppress vascular calcification. There are conflicting reports that show increased or decreased serum fetuin-A levels in patients with coronary artery disease (CAD). Since the role of fetuin-A in atherosclerosis remains still controversial, we aimed to clarify it in this study.
METHODS: We investigated the expression of fetuin-A in atheromatous plaques in CAD patients and restenosis lesions in balloon-injured rat carotid arteries in vivo. We also assessed in vitro effects of fetuin-A on inflammatory molecules in human umbilical vein endothelial cells (HUVECs), oxidized low-density lipoprotein-induced foam cell formation in human monocyte-derived macrophages, and the migration, proliferation, and extracellular matrix expression in human aortic smooth muscle cells (HASMCs) in a serum-free culture system.
RESULTS: Fetuin-A was abundantly expressed in cultured human monocytes, macrophages, fibroblasts, HASMCs, and human coronary artery SMCs, atheromatous plaques in human coronary arteries, and restenosis lesions in rat carotid arteries. In vitro experiments showed that fetuin-A stimulated interleukin-6, monocyte chemotactic protein-1, intercellular adhesion molecule-1, and E-selectin expression in HUVECs. Fetuin-A enhanced macrophage foam cell formation associated with scavenger receptors (CD36 and SR-A) and acyl-CoA:cholesterol acyltransferase-1 up-regulation and ATP-binding cassette transporter A1 down-regulation, and increased cell proliferation and collagen-1 and -3 expression via PI3K/AKT/c-Src/NF-κB/ERK1/2 pathways in HASMCs.
CONCLUSION: Our results indicate that fetuin-A exerts the stimulatory effects on inflammatory responses in HUVECs, macrophage foam cell formation, and proliferation and collagen production in HASMCs, leading to the development of atherosclerosis.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Endothelial cell; Extracellular matrix; Fetuin-A; Macrophage; Restenosis; Vascular smooth muscle cell

Mesh:

Substances:

Year:  2016        PMID: 26828753     DOI: 10.1016/j.atherosclerosis.2016.01.037

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  Usefulness of serum fetuin-A level as a marker of erectile dysfunction.

Authors:  W Kandeel; W El-Shaer; A Sebaey; A A Abou-Taleb; A Fathy; B Elmohamady; A I Mansour
Journal:  Int J Impot Res       Date:  2017-04-20       Impact factor: 2.896

2.  Serum Protein Adsorption Modulates the Toxicity of Highly Positively Charged Hydrogel Surfaces.

Authors:  Yuji Yamada; Galit Fichman; Joel P Schneider
Journal:  ACS Appl Mater Interfaces       Date:  2021-02-16       Impact factor: 10.383

3.  Fetuin-A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high-grade astrocytomas.

Authors:  Gladys N Nangami; Amos M Sakwe; Michael G Izban; Tanu Rana; Philip E Lammers; Portia Thomas; Zhenbang Chen; Josiah Ochieng
Journal:  Cancer Med       Date:  2016-11-23       Impact factor: 4.452

4.  Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist.

Authors:  Kengo Sato; Remina Shirai; Mina Hontani; Rina Shinooka; Akinori Hasegawa; Tomoki Kichise; Tomoyuki Yamashita; Hayami Yoshizawa; Rena Watanabe; Taka-Aki Matsuyama; Hatsue Ishibashi-Ueda; Shinji Koba; Youichi Kobayashi; Tsutomu Hirano; Takuya Watanabe
Journal:  J Am Heart Assoc       Date:  2017-04-14       Impact factor: 5.501

5.  Neopterin Counters Vascular Inflammation and Atherosclerosis.

Authors:  Remina Shirai; Kengo Sato; Tomoyuki Yamashita; Maho Yamaguchi; Taisuke Okano; Kaho Watanabe-Kominato; Rena Watanabe; Taka-Aki Matsuyama; Hatsue Ishibashi-Ueda; Shinji Koba; Youichi Kobayashi; Tsutomu Hirano; Takuya Watanabe
Journal:  J Am Heart Assoc       Date:  2018-02-02       Impact factor: 5.501

6.  Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation.

Authors:  Kengo Sato; Tomoyuki Yamashita; Remina Shirai; Koichiro Shibata; Taisuke Okano; Maho Yamaguchi; Yusaku Mori; Tsutomu Hirano; Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

7.  The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation.

Authors:  Mehrpouya B Mobin; Stefanie Gerstberger; Daniel Teupser; Benedetta Campana; Klaus Charisse; Markus H Heim; Muthiah Manoharan; Thomas Tuschl; Markus Stoffel
Journal:  Nat Commun       Date:  2016-09-26       Impact factor: 14.919

8.  Are Fetuin-A levels beneficial for estimating timing of sepsis occurrence?

Authors:  Hatice B Altinisik; Ugur Altinisik; Sema Uysal; Suzan Sacar; Tuncer Simsek; Yavuz Demiraran
Journal:  Saudi Med J       Date:  2018-07       Impact factor: 1.484

9.  Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-6.

Authors:  Rena Watanabe; Hitomi Watanabe; Yui Takahashi; Miho Kojima; Hanae Konii; Kaho Watanabe; Remina Shirai; Kengo Sato; Taka-Aki Matsuyama; Hatsue Ishibashi-Ueda; Yoshitaka Iso; Shinji Koba; Youichi Kobayashi; Tsutomu Hirano; Takuya Watanabe
Journal:  JACC Basic Transl Sci       Date:  2016-10-31

10.  Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/Macrophage Responses and Hyperlipidemic Mouse Plaque Phenotype.

Authors:  Kengo Sato; Remina Shirai; Maho Yamaguchi; Tomoyuki Yamashita; Koichiro Shibata; Taisuke Okano; Yusaku Mori; Taka-Aki Matsuyama; Hatsue Ishibashi-Ueda; Tsutomu Hirano; Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2018-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.